NEW IPHA RESEARCH SHOWS THAT IRELAND CONTINUES TO LAG EUROPE
Purpose of the bulletin
The Irish Pharmaceutical Healthcare Association (IPHA) will now regularly monitor and report on the availability in other EU countries of new medicines that are awaiting reimbursement in our system. Specifically, we report their availability in the 14 EU Member States which are used to calculate the price in Ireland under the current Framework Agreement with the State (2016-20). These are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the UK.
By monitoring access compared to the 14 nominated EU Member States, IPHA will show the therapies that should be routinely available to clinicians to prescribe for patients in Ireland. If improvements in access are made, as we advocate, we will also show this in regular bulletins. Accordingly, we will also report on the numbers of new medicines approved for reimbursement.
Review of medicines awaiting reimbursement – Ireland and EU-14
The table below shows, as of April 1st
In this context, there is also some welcome progress, given that since the start of the year, seven new IPHA medicines have been approved for reimbursement (up to April 9th).
|Therapy Area||Abridged Indication||Available in how many 14
basket countries as at
1st Feb 18*
|1||Oncology||Relapsed Refractory Mutipled Myeloma||12|
|3||Oncology||Non small cell lung cancer||11|
|4||Muscoloskeletal||Spinal musolar atrophy||9|
|5||Oncology||Non small cell lung cancer||14|
|6||Oncology||Non cmall cell lunh cancer||14|
|7||Oncology||Metastatic breast cancer||13|
|8||Oncology||Breast cancer – neoadjuvant||9|
Source: IPHA members
* The basket of 14 countries consists of: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Portugal Spain, Sweden and the UK
Reflecting on these facts, IPHA Chief Executive OIiver O’Connor said,
“It is not good enough that patients in Ireland should be among the last in western Europe to have access to these new medicines.
“In some cases, these medicines are available in other EU Members States beyond the EU-14.
“With prices now limited to the average of 14 European countries under the Agreement, patients in Ireland should not have to wait longer than patients in comparable European countries for new medicines.
“IPHA members are delivering the promised savings under the Agreement. Its promise to patients of being ‘at the forefront of its European peers in terms of early access’ should also be met by State policy.
“Improved processes, collaborative working with industry and reasonable increases in Exchequer funding will deliver better outcomes for patients.”
Ireland 18th of 26 European countries in access to new medicines
Ireland is now 18th of 26 European countries in 2017 in the availability (reimbursement) of new medicines first authorised by the European Medicines Agency over 2014-16 (see chart below), as shown by new EFPIA research.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, conducts an annual survey on the relative availability of medicines across Europe (including Switzerland and Norway).
The most recent analysis was completed in March and reviews the availability in 2017 of medicines approved by the European Medicines Agency in the previous three years (2014 to 2016).
How to read this chart
The chart shows that
It shows that Ireland is ranked 18 the out of 26 countries on this measure.
Note for Editors
IPHA is the representative organisation of the research based pharmaceutical industry in Ireland. We represent 47 international companies who discover and develop new medicines which can treat or cure many medical conditions and so improve both the quality of life and the life expectancy of patients.
Our industry has had Pricing and Supply Agreements with the State for almost 40 years, with the most recent version in place from August 2016 to July 2020. Estimated savings of €785m that IPHA members will deliver in that period should provide headroom for the HSE to fund new medicines, assisting, but not removing, the need for increased Exchequer funding. While part of the Agreement covers the pricing of medicines (including annual downwards price realignments, price reductions on off-patent products and cash rebates), it also provides a pathway for the reimbursement of new medicines.
The goal of the Agreement, which the State has entered into, is “that Ireland remains at the forefront of its European peers in terms of early access to these new medicines in an affordable manner and within available resources”. Despite this, patients in Ireland do not get access to new medicines as quickly as patients in comparable European countries.
IPHA will next report on the availability of new medicines in July.